Journal of the American Society of Hypertension
Volume 3, Issue 3 , Pages 210-220 , May 2009

Differential effects of extended-release carvedilol and extended-release metoprolol on lipid profiles in patients with hypertension: results of the Extended-Release Carvedilol Lipid Trial

  • Gregg C. Fonarow, MD

      Affiliations

    • Division of Cardiology, University of California, Los Angeles School of Medicine, Los Angeles, California, USA
    • Corresponding Author InformationCorresponding author: Gregg C. Fonarow, MD, Ahmanson-University of California, Los Angeles Cardiomyopathy Center, Division of Cardiology, BH 307 CHS, 10833 LeConte Ave, Los Angeles, California 90095. Tel: 310-206-9112; fax: 310-206-9111.
    • ,
  • Prakash Deedwania, MD

      Affiliations

    • Department of Medicine, VACCHCS/UMC, UCSF Program at Fresno, Fresno, California, USA
    • ,
  • Vivian Fonseca, MD

      Affiliations

    • Endocrinology Department, Tulane University Health Sciences Center, New Orleans, Louisiana, USA
    • ,
  • Richard W. Nesto, MD

      Affiliations

    • Department of Cardiovascular Medicine, Lahey Clinic Medical Center, Burlington, Massachusetts, USA
    • ,
  • Karol Watson, MD

      Affiliations

    • Division of Cardiology, University of California, Los Angeles School of Medicine, Los Angeles, California, USA
    • ,
  • Elizabeth Tarka, MD

      Affiliations

    • GlaxoSmithKline Pharmaceuticals, Philadelphia, Pennsylvania, USA
    • ,
  • Mary Ann Lukas, MD

      Affiliations

    • GlaxoSmithKline Pharmaceuticals, Philadelphia, Pennsylvania, USA
    • ,
  • Anuradha Madan, PhD

      Affiliations

    • GlaxoSmithKline Pharmaceuticals, Philadelphia, Pennsylvania, USA
    • ,
  • Mayadah Shabbout, MS

      Affiliations

    • GlaxoSmithKline Pharmaceuticals, Philadelphia, Pennsylvania, USA

Received 22 August 2008 ,Accepted 19 January 2009.

References 

  1. Castelli WP, Anderson K. A population at risk: prevalence of high cholesterol levels in hypertensive patients in the Framingham Study. Am J Med. 1986;80:23–32
  2. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. JAMA. 2003;290:199–206
  3. Stamler J, Wentworth D, Neaton JD. Prevalence and prognostic significance of hypercholesterolemia in men with hypertension: prospective data on the primary screenees of the Multiple Risk Factor Intervention Trial. Am J Med. 1986;80:33–39
  4. Tse WY, Kendall M. Is there a role for beta-blockers in hypertensive diabetic patients?. Diabetes Med. 1994;11:137–144
  5. Fonarow GC. Managing the patient with diabetes mellitus and heart failure: issues and considerations. Am J Med. 2004;116:76S–788
  6. Bell DS. Use of beta-blockers in the patient with diabetes. Endocrinologist. 2003;13:116–123
  7. Jacob S, Balletshofer B, Henriksen EJ, Volk A, Mehnert B, Loblein K. Beta-blocking agents in patients with insulin resistance: effects of vasodilating beta-blockers. Blood Press. 1999;8:261–268
  8. Ruffolo RR, Gellai M, Hieble JP, Willette RN, Nichols AJ. The pharmacology of carvedilol. Eur J Clin Pharmacol. 1990;38:S82–S88
  9. Jacob S, Rett K, Wicklmayr M, Agrawal B, Augustin HJ, Dietze GJ. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the Carvedilol-Metoprolol Study. J Hypertens. 1996;14:489–494
  10. Giugliano D, Acampora R, Marfella R, de Rose N, Ziccardi P, Ragone R. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension: a randomized, controlled trial. Ann Intern Med. 1997;126:955–959
  11. Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, et al. Metabolic effects of carvedilol in patients with type 2 diabetes mellitus and hypertension. JAMA. 2004;292:2227–2236
  12. Bakris GL, Tarka EA, Waterhouse B, Goulding MR, Madan A, Anderson KM, et al. Cardiovascular risk factors in hypertension: rationale and design of studies to investigate the effects of controlled-release carvedilol on regression of left ventricular hypertrophy and lipid profile. Am J Cardiol. 2006;98:46L–52
  13. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) . Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143–3421
  14. Frikke-Schmidt R, Nordestgaard BG, Agerholm-Larsen B, Schnohr P, Tybjaerg-Hansen A. Context-dependent and invariant associations between lipids, lipoproteins, and apolipoproteins and apolipoprotein E genotype. J Lipid Res. 2000;41:1812–1822
  15. Quade D. Rank analysis of covariance. J Am Stat Assoc. 1967;62:1187–1200
  16. Skulas-Ray AC, West SG, Davidson MH, Kris-Etherton PM. Omega-3 fatty acid concentrates in the treatment of moderate hypertriglyceridemia. Exp Opin Pharmacother. 2008;9:1237–1248
  17. Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, et al. Triglycerides and the risk of coronary heart disease—10,158 incident cases among 262,525 participants in 29 western prospective studies. Circulation. 2007;115:450–458
  18. Jeppesen J, Hein H, Suadicani P, Gyntelberg F. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation. 1998;97:1026–1036
  19. Durrington PN. Triglycerides are more important in atherosclerosis than epidemiology has suggested. Atherosclerosis. 1998;141:S57–S62
  20. Despres J-P, Lamarche B, Mauriege P, Cantin B, Dagenais G, Moorjani S, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med. 1996;334:952–957
  21. Hu G. The DECODE Insulin Study Group. Plasma insulin and cardiovascular mortality in non-diabetic European Men and Women: a meta-analysis of data from eleven prospective studies. Diabetologia. 2004;47:1245–1256
  22. Sharp RP, Sirajuddin R, Sharief IM. Impact of carvedilol on the serum lipid profile. Ann Pharmacother. 2008;42:564–571
  23. Dell'Omo G, Penno G, Del Prato S, Pedrinelli R. Doxazosin in metabolically complicated hypertension. Exp Rev Cardiovasc Ther. 2007;5:1027–1035

 Drs. Fonarow, Deedwania, Fonseca, Nesto, and Waston have served as consultants to GlaxoSmithKline. Drs. Tarka, Lukas, Madan, and Ms. Shabbout are employees of GlaxoSmithKline.

PII: S1933-1711(09)00009-6

doi: 10.1016/j.jash.2009.01.004

Journal of the American Society of Hypertension
Volume 3, Issue 3 , Pages 210-220 , May 2009

Article Tools

* Image Usage & Resolution